Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Clinical features and prognosis of thymic neuroendocrine tumours associated with multiple endocrine neoplasia type 1: A single‐centre study, systematic review and meta‐analysis
Ye, Lei , Wang, Weixi , Wang, Weixi, Ospina, Naykky Singh , Jiang, Lei , Christakis, Ioannis , Lu, Jieli , Zhou, Yulin , Cao, Yanan , Wang, Shu , Ning, Guang , Wang, Weiqing, Wang, Weiqing, Ospina, Naykky Singh , Wang, Weixi, Zhu, Wei Ping , Perrier, Nancy D. , Young, William F. , Wang, Weiqing, Wang, Weiqing, Singh Ospina, Naykky

Mayo Clinic

Clinical Endocrinology | September 20, 2017 | Volume: 87 | Issue: 6 | Pages: 706-716

10.1111/cen.13480 | PMID 28940393 Get It

SummaryObjectiveThymic neuroendocrine tumour (TH‐NET) accounts for almost 20% of multiple endocrine neoplasia type 1 (MEN1)‐associated mortality. Identifying risk factors for the development of these rare tumours and prognostic factors for clinical outcomes will be helpful in clinical practice.Design and PatientsWe performed a retrospective analysis of patients treated for TH‐NET associated with MEN1 in a single institution and meta‐analysis of literature reports. We used a fixed effect model to pool results across studies to evaluate the prevalence, clinical features and prognosis.ResultsTH‐NET was detected in 9 (7.4%) of 121 patients with MEN1 seen in our institution, and 5 (55.6%) were women. Seven additional studies were identified through a systematic review of the literature. The pool estimate of TH‐NET prevalence was 3.7% (n = 99) in MEN1 (n = 2710), sex ratio was 79:20 (male vs female), and the median age at diagnosis was 43.0 years (range, 16.0‐72.0 years). Forty‐three patients died with a median survival time of 8.4 years. Older age at diagnosis (HR = 1.4, 95% CI = 1.0‐1.8, P = .03), maximum tumour diameter (HR = 1.5, 95% CI = 1.0‐2.3, P = .04) and presence of metastasis (HR = 1.6, 95% CI = 1.0‐2.5, P = .04) were associated with worse outcome. A male predominance (91.9% vs 59.5%, P < .001) and history of smoking (59.0% vs 23.5%, P = .015) were more common in American/European series compared to Asian reports.ConclusionTH‐NET is a rare but fatal component of MEN1. Earlier detection of TH‐NET in patients with MEN1 may be recommended which should theoretically result in better outcomes. Different genetic backgrounds (race) appear to result in clinical difference.
Intrainstitutional EHR collections for patient‐level information retrieval
Wu, Stephen , Wang, Yanshan , Timmons, Tamara, Uppili, Harsha, Bedrick, Steven , Liu, Sijia , Cheney, Tamara P. , Hersh, William , Liu, Hongfang , Wang, Yanshan , Bedrick, Steven D

Mayo Clinic

Journal of the Association for Information Science and Technology | September 18, 2017 | Volume: 68 | Issue: 11 | Pages: 2636-2648

10.1002/asi.23884 Get It

Research in clinical information retrieval has long been stymied by the lack of open resources. However, both clinical information retrieval research innovation and legitimate privacy concerns can be served by the creation of intrainstitutional, fully protected resources. In this article, we provide some principles and tools for information retrieval resource‐building in the unique problem setting of patient‐level information retrieval, following the tradition of the Cranfield paradigm. We further include an analysis of parallel information retrieval resources at Oregon Health & Science University and Mayo Clinic that were built on these principles.
Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma
Davila, Jaime , Starr, Jason S. , Attia, Steven , Knudson, Ryan A., Necela, Brian M. , Sarangi, Vivekananda , Sun, Zhifu , Ren, Yingxue , Casler, John D., Menke, David M. , Oliver, Gavin R. , Copland, John A. , Parker, Alexander S. , Kocher, Jean-Pierre A., Thompson, E. Aubrey , Smallridge, Robert C., Asmann, Yan W. , Davila, Jaime I, Sun, Zhifu , Davila, Jaime I , Wang, Chen , Joseph, Richard W.

Mayo Clinic

Rare Tumors | September 15, 2017 | Volume: 9 | Issue: 2 | Pages: 50-53

10.4081/rt.2017.6834 | PMID 28975018 Get It

We previously reported an extremely rare case of follicular dendritic cell sarcoma (FDCS) presented as a thyroid mass. Given the rarity of this disease, there are no personalized and molecularly targeted treatment options due to the lack of knowledge in the genomic makeup of the tumor. A 44-year-old white woman was diagnosed with an extranodal FDCS in thyroid. The patient underwent a total thyroidectomy, central compartment dissection, parathyroid re-implantation, and adjuvant radiation therapy. Tumor DNA sequencing of 236 genes by FoundationOne panel found truncating mutations in PTEN and missense mutations in RET and TP53. However, patient-matched germline DNA was not sequenced which is critical for identification of true somatic mutations. Furthermore, the FoundationOne panel doesn't measure genomic rearrangements which have been shown to be abundant in sarcomas and are associated with sarcoma tumorigenesis and progression. In the current study, we carried out comprehensive genomic sequencing of the tumor, adjacent normal tissues, and patient-matched blood, in an effort to understand the genomic makeup of this rare extranodal FDCS and to identify potential therapeutic targets. Eighty-one somatic point mutations were identified in tumor but not in adjacent normal tissues or blood. A clonal truncating mutation in the CLTCL1 gene, which stabilizes the mitotic spindle, was likely a driver mutation of tumorigenesis and could explain the extensive copy number aberrations (CNAs) and genomic rearrangements in the tumor including a chr15/chr17 local chromothripsis resulted in 6 expressed fusion genes. The fusion gene HDGFRP3→SHC4 led to a 200-fold increase in the expression of oncogene SHC4 which is a potential target of the commercial drug Dasatinib. Missense mutations in ATM and splice-site mutation in VEGFR1 were also detected in addition to the TP53 missense mutation reported by FoundationOne.
Exuberant nodal proliferation of mature plasmacytoid dendritic cells in a patient with chronic myelomonocytic leukemia
Wang, Huan‐You , Feldman, Andrew L. , Feldman, Andrew L

Mayo Clinic

Blood | September 14, 2017 | Volume: 130 | Issue: 11 | Pages: 1387-1387

10.1182/blood-2017-04-779017 | PMID 28912296 Get It

Paracrine Secretion of Transforming Growth Factor β by Ductal Cells Promotes Acinar-to-Ductal Metaplasia in Cultured Human Exocrine Pancreas Tissues
Liou, Geou‐Yarh , Yin, Xue, Liu, Chengyang , Sun, Lu‐Zhe , Störz, Peter , Wang, Pei , Akanuma, Naoki, Liou, Geou-Yarh , Akanuma, Naoki , Liu, Jun , Bejar, Kaitlyn

Mayo Clinic

Pancreas | September 11, 2017 | Volume: 46 | Issue: 9 | Pages: 1202-1207

10.1097/mpa.0000000000000913 | PMID 28902792 Get It

Objective We aimed to evaluate the contribution of acinar-to-ductal metaplasia (ADM) to the accumulation of cells with a ductal phenotype in cultured human exocrine pancreatic tissues and reveal the underlying mechanism. Methods We sorted and cultured viable cell populations in human exocrine pancreatic tissues with a flow cytometry–based lineage tracing method to evaluate possible mechanisms of ADM. Cell surface markers, gene expression pattern, and sphere formation assay were used to examine ADM. Results A large proportion of acinar cells gained CD133 expression during the 2-dimensional culture and showed down-regulation of acinar markers and up-regulation of ductal markers, assuming an ADM phenotype. In a serum-free culture condition, ADM induction was mainly dependent on transforming growth factor β (TGF-β) secreted from cultured ductal cells. Human acinar cells when cultured alone for a week in a serum-free condition do not undergo ADM. However, serum may contain other factors besides TGF-β to induce ADM in human acinar cells. In addition, we found that TGF-β cannot induce ADM of murine acinar cells. Conclusions Ductal cells are the major source of TGF-β that induces ADM in cultured human exocrine pancreatic tissues. This culture system might be a useful model to investigate the mechanism of ADM in human cells.
Network-directed cis-mediator analysis of normal prostate tissue expression profiles reveals downstream regulatory associations of prostate cancer susceptibility loci
McDonnell, Shannon K. , Fogarty, Zachary C. , Cheville, John C. , Riska, Shaun M., Baheti, Saurabh , Weber, Alexandra M. , Nair, Asha, O’Brien, Daniel R. , Davila, Jaime , Schaid, Daniel J. , Thibodeau, Stephen N. , Fogarty, Zach, Riska, Shaun, Nair, Asha A, Fogarty, Zachary C , Davila, Jaime I , Larson, Nicholas B. , Larson, Melissa C. , Wang, Liang , McDonnell, Shannon K

Mayo Clinic

Oncotarget | September 8, 2017 | Volume: 8 | Issue: 49 | Pages: 85896-85908

10.18632/oncotarget.20717 | PMID 29156765 Get It

Dectin-2 Is a C-Type Lectin Receptor that Recognizes Pneumocystis and Participates in Innate Immune Responses
Hebrink, Deanne, Jenson, Paige E., Marsolek, Paige L., Wüthrich, Marcel , Wang, Huafeng , Kottom, Theodore J. , Hebrink, Deanne M, Klein, Bruce S. , Yamasaki, Sho , Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | September 8, 2017 | Volume: 58 | Issue: 2 | Pages: 232-240

10.1165/rcmb.2016-0335oc | PMID 28886250 Get It

Abstract Pneumocystis is an important fungal pathogen that causes life-threatening pneumonia in patients with AIDS and malignancy. Lung fungal pathogens are recognized by C-type lectin receptors (CLRs), which bind specific ligands and stimulate innate immune responses. The CLR Dectin-1 was previously shown to mediate immune responses to Pneumocystis spp. For this reason, we investigated a potential role for Dectin-2. Rats with Pneumocystis pneumonia (PCP) exhibited elevated Dectin-2 mRNA levels. Soluble Dectin-2 carbohydrate-recognition domain fusion protein showed binding to intact Pneumocystis carinii (Pc) and to native Pneumocystis major surface glycoprotein/glycoprotein A (Msg/gpA). RAW macrophage cells expressing V5-tagged Dectin-2 displayed enhanced binding to Pc and increased protein tyrosine phosphorylation. Furthermore, the binding of Pc to Dectin-2 resulted in Fc receptor-γ–mediated intracellular signaling. Alveolar macrophages from Dectin-2–deficient mice (Dectin-2−/−) showed significant decreases in phospho-Syk activation after challenge with Pc cell wall components. Stimulation of Dectin-2−/− alveolar macrophages with Pc components showed significant decreases in the proinflammatory cytokines IL-6 and TNF-α. Finally, during infection with Pneumocystis murina, Dectin-2−/− mice displayed downregulated mRNA expression profiles of other CLRs implicated in fungal immunity. Although Dectin-2−/− alveolar macrophages had reduced proinflammatory cytokine release in vitro, Dectin-2−/− deficiency did not reduce the overall resistance of these mice in the PCP model, and organism burdens were statistically similar in the long-term immunocompromised and short-term immunocompetent PCP models. These results suggest that Dectin-2 participates in the initial innate immune signaling response to Pneumocystis, but its deficiency does not impair resistance to the organism.
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
Moigne, Ronan Le , Aftab, Blake T. , Djakovic, Stevan, Dhimolea, Eugen , Murnane, Megan, King, Emily M. , Soriano, Ferdie, Menon, Mary-Kamala, Wu, Zhi , Lee, Grace J. , Lam, Christine , Rice, Julie , Wang, Jinhai , Chesi, Marta , Bergsagel, P. Leif , Kraus, Marianne , Driessen, Christoph , Soly, Szerenke Kiss Von, Yakes, F. Michael, Wustrow, David J., Shawver, Laura K. , Zhou, Han-Jie , Wolf, Jeffrey L. , Mitsiades, Constantine S. , Rolfe, Mark , Bergsagel, P. Leif , Junior, Eduardo Alves do Valle , Wong, Stephen T.C. , Yao, Bing , Wiita, Arun P. , Martin, Thomas G. , Anderson, Daniel J.

Mayo Clinic

Molecular Cancer Therapeutics | September 6, 2017 | Volume: 16 | Issue: 11 | Pages: 2375-2386

10.1158/1535-7163.mct-17-0233 | PMID 28878026 Get It

Abstract Inhibition of the AAA ATPase, p97, was recently shown to be a novel method for targeting the ubiquitin proteasome system, and CB-5083, a first-in-class inhibitor of p97, has demonstrated broad antitumor activity in a range of both hematologic and solid tumor models. Here, we show that CB-5083 has robust activity against multiple myeloma cell lines and a number of in vivo multiple myeloma models. Treatment with CB-5083 is associated with accumulation of ubiquitinated proteins, induction of the unfolded protein response, and apoptosis. CB-5083 decreases viability in multiple myeloma cell lines and patient-derived multiple myeloma cells, including those with background proteasome inhibitor (PI) resistance. CB-5083 has a unique mechanism of action that combines well with PIs, which is likely owing to the p97-dependent retro-translocation of the transcription factor, Nrf1, which transcribes proteasome subunit genes following exposure to a PI. In vivo studies using clinically relevant multiple myeloma models demonstrate that single-agent CB-5083 inhibits tumor growth and combines well with multiple myeloma standard-of-care agents. Our preclinical data demonstrate the efficacy of CB-5083 in several multiple myeloma disease models and provide the rationale for clinical evaluation as monotherapy and in combination in multiple myeloma. Mol Cancer Ther; 16(11); 2375–86. ©2017 AACR.
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
Javed, Ammar A. , Thoburn, Christopher J. , Wong, Fay , Tie, Jeanne , Allen, Peter J., Schattner, Mark , Petersen, Gloria M. , Hong, Seung‐Mo , Falconi, Massimo , Weiss, Matthew J. , Ahuja, Nita , He, Jin , Makary, Martin A. , Molin, Marco Dal , Li, Lu , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Hruban, Ralph H. , Wolfgang, Christopher L. , Papadopoulos, Nickolas , Kinzler, Kenneth W. , Vogelstein, Bert , Lennon, Anne Marie , Thoburn, Christopher , Javed, Ammar A , Tie, Jeanne , Lennon, Anne Marie , Cohen, Joshua D. , Gibbs, Peter , Schmidt, Christian Max , YIP-SCHNEIDER, Michele T. , Brand, Randall E. , Singhi, Aatur Dilip , Kim, Song Cheol , Doglioni, Claudio , Maitra, Anirban , Hanash, Samir , Wang, Yuxuan , Schaefer, Joy , Popoli, Maria , Goggins, Michael , Klein, Alison P. , Tomasetti, Cristian , Massimo, Falconi

Mayo Clinic

Proceedings of the National Academy of Sciences | September 5, 2017 | Volume: 114 | Issue: 38 | Pages: 10202-10207

10.1073/pnas.1704961114 | PMID 28874546 Get It

Significance Few patients with pancreatic cancer survive longer than 5 y, in part because most patients are identified only after their disease has progressed to an advanced stage. In this study, we show how combining mutations in circulating tumor DNA (ctDNA) with protein markers can result in a screening test with improved sensitivity while retaining specificity. The combination of the ctDNA and protein markers was superior to any single marker. Moreover, the combination detected nearly two-thirds of pancreatic cancers that had no evidence of distant metastasis at the time of surgical resection. The strategy may represent an approach to detect cancers of many types at an earlier stage.